Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile

4 Feb 2022

Abstract excerpt

Clostridium (Clostridioides) difficile infection (CDI) remains an urgent threat to patients in health systems worldwide. Recurrent CDI occurs in up to 30% of cases due to sustained dysbiosis of the gut microbiota which normally protects against CDI. Associated costs of initial and recurrent episodes of CDI impose heavy financial burdens on health systems. Vancomycin and metronidazole have been the mainstay of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clostridium difficile and Clostridium perfringens research
Share to Microscopic Colitis
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35119124
DOI: 10.1111/lam.13664

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficilePMID 35119124Read ↗

Probiotics: insights and new opportunities for Clostridioides difficile interventionSemantic proximity Read ↗

Clinical and pharmacoeconomic evaluation of fidaxomicin in patients over 65 years of age and immunocompromised patients with recurrent and refractory Clostridioides difficile infectionSemantic proximity Read ↗

Advancements in Novel Live Biotherapeutic Products for Clostridioides difficile Infection PreventionSemantic proximity Read ↗

Comparison of fidaxomicin, thuricin CD, vancomycin and nisin highlights the narrow spectrum nature of thuricin CDSemantic proximity Read ↗

Microbiota restoration reduces antibiotic-resistant bacteria gut colonization in patients with recurrent Clostridioides difficile infection from the open-label PUNCH CD studySemantic proximity Read ↗

The novel DNA binding mechanism of ridinilazole, a precision Clostridiodes difficile antibiotic.Semantic proximity Read ↗

In vivo emergence of a still uncommon resistance to fidaxomicin in the urgent antimicrobial resistance threat Clostridioides difficileSemantic proximity Read ↗

Antibacterials Developed to Target a Single Organism: Mechanisms and Frequencies of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compounds Fidaxomicin and LFF571.Semantic proximity Read ↗

Slow and incomplete recovery of gut microbiome in Clostridioides difficile patients treated with metronidazoleSemantic proximity Read ↗

Minimum inhibitory concentrations increase in Clostridioides difficile isolates from patients with recurrence: results from a retrospective single-centre cohort studySemantic proximity Read ↗

Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.Semantic proximity Read ↗

High-throughput screening identifies a novel natural product-inspired scaffold capable of inhibiting Clostridioides difficile in vitroSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.